Stan B Kaye

Stan B Kaye

UNVERIFIED PROFILE

Are you Stan B Kaye?   Register this Author

Register author
Stan B Kaye

Stan B Kaye

Publications by authors named "Stan B Kaye"

Are you Stan B Kaye?   Register this Author

75Publications

1854Reads

7Profile Views

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

Eur J Cancer 2018 05 31;95:20-29. Epub 2018 Mar 31.

Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK; Gynaecology Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.02.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296443PMC
May 2018

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Lung Cancer 2017 09 15;111:6-11. Epub 2017 Jun 15.

Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.06.005DOI Listing
September 2017

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

Eur J Cancer 2017 05 6;76:52-59. Epub 2017 Mar 6.

Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK; The Institute of Cancer Research, Cotswold Road, London SM2 5NG, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.01.020DOI Listing
May 2017

Trabectedin as a chemotherapy option for patients with BRCA deficiency.

Cancer Treat Rev 2016 Nov 15;50:175-182. Epub 2016 Sep 15.

Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, 19, 20156 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.09.009DOI Listing
November 2016

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.

Mol Cancer Ther 2016 06 5;15(6):1412-24. Epub 2016 Apr 5.

Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321508PMC
June 2016

PARP inhibitors: the race is on.

Br J Cancer 2016 Mar;114(7):713-5

Drug Development Unit, Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/bjc201667
Publisher Site
http://dx.doi.org/10.1038/bjc.2016.67DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984871PMC
March 2016

Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases.

Thromb Res 2016 Jan 22;137:30-35. Epub 2015 Nov 22.

Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Lanesborough Wing, St. George's Hospital, Blackshaw Road, London, SW17 0QT, United Kingdom; Department of Gynaecological Oncology, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, United Kingdom.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00493848153020
Publisher Site
http://dx.doi.org/10.1016/j.thromres.2015.11.030DOI Listing
January 2016

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Eur J Cancer 2014 Aug 10;50(12):2050-6. Epub 2014 Jun 10.

Gustave Roussy Cancer Campus, DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Villejuif, France; Université Paris-Sud XI, Orsay, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.04.030DOI Listing
August 2014

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.

Clin Cancer Res 2013 Oct 6;19(19):5485-93. Epub 2013 Aug 6.

Authors' Affiliations: The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton; Edinburgh Cancer Research UK Center, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh; The Cancer Research UK Gene Function Laboratory; Breakthrough Breast Cancer Research Center; Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom; University of California San Francisco, San Francisco, California; Department of Medical Oncology, Prince of Wales Clinical School, Prince of Wales Hospital, Sydney, Australia; The Chaim Sheba Medical Center, Tel Hashomer, Israel; Princess Margaret Hospital, Toronto, Canada; Oncologisch Centrum Vrije Universiteit Brussel, Brussels, Belgium; and Dana Farber Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1262DOI Listing
October 2013

Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.

Eur J Cancer 2013 Apr 19;49(6):1246-53. Epub 2012 Dec 19.

Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.11.016DOI Listing
April 2013

Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Nat Rev Cancer 2013 04 21;13(4):273-82. Epub 2013 Feb 21.

The Institute of Cancer Research/Royal Marsden Hospital, Medicine, Downs Road, Sutton SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673904PMC
April 2013

Identifying prognostic signatures in the blood of ovarian cancer patients.

Gynecol Oncol 2013 Jan;128(1):1-2

The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK; Division of Clinical Studies, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.11.011DOI Listing
January 2013

Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.

Radiology 2012 Nov 13;265(2):426-36. Epub 2012 Aug 13.

Cancer Research UK and EPSRC Imaging Centre and Drug Development Unit of Section of Medicine, Institute of Cancer Research and Royal Marsden Hospital, MRI Unit, Downs Road, Sutton, Surrey SM2 5PT, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.12112565DOI Listing
November 2012

Combining antiangiogenics to overcome resistance: rationale and clinical experience.

Clin Cancer Res 2012 Jul 30;18(14):3750-61. Epub 2012 Apr 30.

Division of Clinical Sciences, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1275DOI Listing
July 2012

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

Mol Cancer Ther 2012 Jul 3;11(7):1609-17. Epub 2012 May 3.

Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutic, The Institute of Cancer Research, Sutton,United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0996DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630857PMC
July 2012

Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?

Nat Rev Clin Oncol 2012 Feb 28;9(4):194-6. Epub 2012 Feb 28.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.28DOI Listing
February 2012

Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients.

Radiology 2011 Oct 9;261(1):182-92. Epub 2011 Aug 9.

Cancer Research-UK and EPSRC Cancer Imaging Centre, Research Data Management and Statistics Unit, and Department of Gynaecological Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey SM2 5PT, England.

View Article

Download full-text PDF

Source
http://pubs.rsna.org/doi/10.1148/radiol.11110577
Publisher Site
http://dx.doi.org/10.1148/radiol.11110577DOI Listing
October 2011

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients.

Cancer Chemother Pharmacol 2011 Aug 11;68(2):423-9. Epub 2010 Nov 11.

Royal Marsden Hospital, London, SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1484-9DOI Listing
August 2011

Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials.

Clin Cancer Res 2011 Aug 29;17(15):5188-96. Epub 2011 Apr 29.

Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-3019DOI Listing
August 2011

Emerging therapeutic targets in endometrial cancer.

Nat Rev Clin Oncol 2011 May 11;8(5):261-71. Epub 2011 Jan 11.

The Breakthrough Breast Cancer Research Center, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK. konstantin.dedes@ usz.ch

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2010.216DOI Listing
May 2011

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

Nat Rev Clin Oncol 2011 May 5;8(5):302-6. Epub 2011 Apr 5.

Drug Development Unit, Royal Marsden Hospital, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.42DOI Listing
May 2011

Weekly paclitaxel in the treatment of recurrent ovarian cancer.

Nat Rev Clin Oncol 2010 Oct 3;7(10):575-82. Epub 2010 Aug 3.

Section of Medicine, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2010.120DOI Listing
October 2010

PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.

Curr Opin Oncol 2010 Sep;22(5):473-80

The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32833b5126DOI Listing
September 2010

Making the best of PARP inhibitors in ovarian cancer.

Nat Rev Clin Oncol 2010 Sep 10;7(9):508-19. Epub 2010 Aug 10.

The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2010.116DOI Listing
September 2010

Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.

Nat Rev Clin Oncol 2010 Jul 13;7(7):381-93. Epub 2010 Apr 13.

Section of Magnetic Resonance, Cancer Research UK and EPSRC Cancer Imaging Center, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2010.47DOI Listing
July 2010

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Cancer J 2009 Sep-Oct;15(5):406-20

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, UK.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/journalppo/2009/10000/Biomarker
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0b013e3181bd0445DOI Listing
April 2010

Current treatment and clinical trials in ovarian cancer.

Expert Opin Investig Drugs 2010 Apr;19(4):521-34

Royal Marsden Hospital, The Gynecology Unit, Department of Medicine, Sycamore House, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543781003647966DOI Listing
April 2010

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

N Engl J Med 2009 Jul 24;361(2):123-34. Epub 2009 Jun 24.

Drug Development Unit, Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa0900212DOI Listing
July 2009

Beyond chemotherapy: targeted therapies in ovarian cancer.

Nat Rev Cancer 2009 Mar;9(3):167-81

The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrc2583
Publisher Site
http://dx.doi.org/10.1038/nrc2583DOI Listing
March 2009

Ovarian cancer: can we reverse drug resistance?

Adv Exp Med Biol 2008 ;622:153-67

Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-0-387-68969-2_13DOI Listing
July 2008

Reversal of drug resistance in ovarian cancer: where do we go from here?

Authors:
Stan B Kaye

J Clin Oncol 2008 Jun;26(16):2616-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.16.2123DOI Listing
June 2008

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.

Clin Cancer Res 2007 Dec;13(23):7191-8

Section of Medicine, The Institute of Cancer Research, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0362DOI Listing
December 2007

Bleomycin and scuba diving: where is the harm?

Lancet Oncol 2007 Nov;8(11):954-5

Erasmus University Medical Centre, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(07)70321-2DOI Listing
November 2007

Expression profiling and individualisation of treatment for ovarian cancer.

Curr Opin Pharmacol 2006 Aug 5;6(4):345-9. Epub 2006 Jun 5.

Section of Medicine, Institute for Cancer Research, Royal Marsden Hospital, Sycamore House, Downs Road, Sutton, Surrey, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2006.02.007DOI Listing
August 2006

Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial.

J Clin Oncol 2005 Dec;23(34):8802-11

Department of Gynaecological-Oncology, Southampton University Hospitals Trust, Southampton SO16, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.02.1287DOI Listing
December 2005

Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.

Drug Resist Updat 2005 Oct 17;8(5):311-21. Epub 2005 Oct 17.

The Institute of Cancer Research, 15 Cotswold Road, Sutton SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drup.2005.09.001DOI Listing
October 2005

Docetaxel in the management of ovarian cancer.

Expert Rev Anticancer Ther 2005 Apr;5(2):203-14

Royal Marsden Hospital Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.5.2.203DOI Listing
April 2005

Ovarian cancer: strategies for overcoming resistance to chemotherapy.

Nat Rev Cancer 2003 Jul;3(7):502-16

Section of Medicine, Institute for Cancer Research, Sutton, Surrey SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc1123DOI Listing
July 2003

Ovarian cancer: progress and continuing controversies in management.

Eur J Cancer 2002 Sep;38(13):1701-7

Department of Medical Oncology, Royal Marsden Hospital, Downs Road, Surrey Sutton, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0959-8049(02)00161-2DOI Listing
September 2002